• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5496 | Ordered by Date (descending)
 1 2 3 ... 23 24 25 ... 53 54 55  

Deal: Collaboration or Financing	Date
Gene Predictis–OTHER: investment, 201512 1st external invesment CHF0.5m by a strategic investor from Swiss healthcare system	2015-12-01
MATURA Consortium–Protagen: personalised medicine, 201512– project member collab research treatment response predictors in rheumatoid arthritis	2015-12-01
Novartis–Polyphor: drug discovery services, 201512 collab RnD extension working towards nomination of PEN macrocycle drug candidate	2015-12-01
Santhera–SEVERAL: investment, 201512 capital increase CHF54.8m private placement 590k new shares CHF93/share	2015-12-01
Cypher Genomics–Human Longevity: investment, 201511 acquisition €na of Cypher Genomics by HLI	2015-11-30
Poli Group–Almirall: investment, 201511– acquisition 100% of Poli Group Holding by Almirall ANNOUNCED	2015-11-30
Alvogen–Insilico Biotechnology: bioinformatics, 201511– collab Alvotech using Insilico simulation s/w to develop biosimilars using mammalian cells	2015-11-27
TiGenix–Cormorant Asset Management: investment, 201511 private placement totalling €8.7m incl €4.7m to Cormorant Global Healthcare	2015-11-25
TiGenix–SEVERAL: investment, 201511 private placement €8.7m with 9.1m new shares €0.95/share to Cormorant + European institutional investors	2015-11-25
BMS–Life Sciences Partners: venture capital, 201511– strategic collab identifying life sciences innovation in Europe incl BMS investment in LSP 5 fund	2015-11-24
Life Sciences Partners–BMS: investment, 201511 significant investment in LSP 5 fund by BMS as part of strategic collaboration	2015-11-24
Life Sciences Partners–Hume Brophy: public relations, 201511 service existent by Hume Brophy	2015-11-24
ObsEva–MacDougall Biomedical Communications: public relations, 201511 service existent by MacDougall	2015-11-23
ObsEva–SEVERAL: investment, 201511 financing round Series B CHF60m ($60m) incl HBM + NEA + Orbimed + Rock Springs + Sofinnova	2015-11-23
ObsEva–Kissei: oral GnRH antagonist, 201511– acquisition €na excl rights to develop + commericalise KLH-2109 outside of Asia	2015-11-20
Merck (DE)–Univ Cape Town: malaria drug, 201511– collab research with UCT H3D to develop anti-malarial drug candidates using Merck compound library	2015-11-19
Greiner–Oncgnostics: cervical cancer test, 201511– distribution of GynTect test by Greiner Bio-One in DACH + FR + GB + Benelux	2015-11-18
Novartis–Thermo Fisher: molecular companion diagnostics, 201511– collab developm NGS-based CDx for NSCLC with Pfizer	2015-11-18
Oncotest–Charles River: investment, 201511 acquisition of Oncotest GmbH for €34m in cash + €2m milestones	2015-11-18
Biophytis–LifeSci: public relations, 201511 service existent by LifeSci Advisors	2015-11-17
Kymab–Genedata: bioinformatics, 201511– license to Genedata Biologics for HT antibody discovery w Kymouse technology	2015-11-17
Molecular Health–Hopp Group: investment, 201511 private financing round totalling €25m led by existing investor Dievini	2015-11-16
Molecular Health–SEVERAL: investment, 201511 private financing round €25m led by existing investor Dievini	2015-11-16
Greiner–Scienion: print/spotting technology, 201511 collab integrating sciFlexarrayer techn w Genspeed platform for rapid Dx tests	2015-11-13
Curetis–CMS: legal services, 201511 service CMS advisor for Curetis IPO at Euronext Amsterdam + Brussels	2015-11-11
Kuros–SEVERAL: investment, 201511 2nd CHF5m closing from new + existeng investors bringing financing round to CHF20m	2015-11-11
Nestlé–ImaBiotech: mass spectrometry services, 201511– supply Multimaging services for Galderma’s drug development	2015-11-10
Pierre Fabre–EPFL: biochips, 201511– collab research use of biosensor chips in clinical drug development	2015-11-10
Syngenta–DSM: microbial agricultural solutions, 201511– collab developm microbial-based solutions incl bio-controls + bio-pesticides + bio-stimulants	2015-11-06
Probiodrug–SEVERAL: investment, 201511 private placement €13.5m w 677k new shares at €20/share to Europ + US investors	2015-11-05
Roche–Polyphor: antibiotic, 201311–201511 license excl ww to POL7080 CHF35m upfront + CHF465m milestones + royalties TERMINATED by Roche 11/15	2015-11-04
CureVac–Baillie Gifford: investment, 201511 private placement totalling €100m incl new + lead investor Baillie Gifford	2015-11-03
CureVac–Chartwave: investment, 201511 private placement totalling €100m incl new investor Chartwave Ltd	2015-11-03
CureVac–Coppel Group: investment, 201511 private placement totalling €100m incl new investor Coppel family	2015-11-03
CureVac–Elma Investments: investment, 201511 private placement totalling €100m incl new investor Elma Investments Ltd	2015-11-03
CureVac–Gates Foundation: investment, 201511 private placement totalling €100m incl existing investor Bill & Melinda Gates Foundation	2015-11-03
CureVac–Hopp Group: investment, 201511 private placement totalling €100m incl existing investor dievini Hopp Biotech Holding GmbH & Co KG	2015-11-03
CureVac–Rittershaus: legal services, 201511 supply legal advisor for €100m financing round	2015-11-03
CureVac–SEVERAL: investment, 201511 private placement €100m led by Baillie Gifford	2015-11-03
CureVac–Sigma Group: investment, 201511 private placement totalling €100m incl new investor Sigma Group	2015-11-03
Sanofi–BioNTech: cancer immunotherapy, 201511– collab + license agreement for mRNA-based therapeutics	2015-11-03
Wageningen Univ–Thermo Fisher: mass spectrometer, 201511 supply existent use of Q Exactive GC system by Marc Tienstra at RIKILT	2015-11-03
Lead Pharma–Akampion: public relations, 201511 service existent by Akampion	2015-11-02
Merck (DE)–Selvita: drug discovery services, 2013–2015 collab 2-year partnership in cancer metabolism	2015-11-02
Merck (DE)–Selvita: drug discovery services, 201511– collab €na 3-year r+d small-molecule cancer drugs	2015-11-02
Omeicos–Germany (govt): grant, 201511– BMBF research grant €1.7m	2015-11-02
Apta Biosciences–EU (govt): grant, 201511– Horizon 2020 grant €940k as part of MARA project to develop new antiinfectives	2015-11-01
BFCC project–EU (govt): grant, 201511– grant €3.6m for Baltic Fracture Competence Centre from Interreg Baltic Sea Region Programme	2015-11-01
BFCC project–Hamburg (govt): healthcare, 201511– Life Science Nord Management GmbH is lead partner in Baltic Fracture Competence Centre	2015-11-01
European AIDS Vaccine Initiative–EU (govt): grant, 201511– €23m Horizon 2020 grant for EAVI 2020 for 5 years to develop HIV vaccines	2015-11-01
MARA project–EU (govt): grant, 201511– Horizon 2020 grant €3m to develop new anti-infectives	2015-11-01
MTIP MedTech Innovation Partners–SEVERAL: investment, 201511–201604 1st closing CHF30m of 1st MTIP Fund	2015-11-01
Tusk Therapeutics–SEVERAL: investment, 201511 financing round Series A €30m	2015-11-01
BioGenes–PERSON: investment, 201510 MBO €na from GUB Unternehmensbeteiligungen + VC Fonds Berlin by the two founders	2015-10-31
Co.don–SEVERAL: investment, 201510–201511 capital increase €5m with 2.5m new shares at €2/share w existing + new investors	2015-10-30
GeneWake–R-Biopharm: investment, 201510 acquisition of GeneWake GmbH which had filed for bankruptcy in February 2015	2015-10-29
High-Tech Gründerfonds–Donghai Securities: business services, 201510– collab service for accessing Chinese capital + markets	2015-10-29
Sigma-Aldrich–Olink: research reagents, 201510 acquisition of Duolink product portfolio by Sigma-Aldrich	2015-10-29
BioLamina–Cevec: rec protein production technology, 201510– license €na to CAP Go technology for laminins for ex vivo cell culture therapies	2015-10-28
Cevec–iBET (PT): rec protein production, 201510 collab existent GenIbet is joint venture partner of Cevec	2015-10-28
Curetis–Stratec: investment, 201510 existent Stratec Biomedical AG is existing investor	2015-10-28
Danaher–Univ Manchester: mass spectrometry, 201510– collab joint Sciex Multi-omics Centre for Precision Medicine tog w Stoller Centre	2015-10-28
Sias–Tecan: investment, 201510–201511 acquisition CHF25m in cash	2015-10-28
Univ Manchester–Danaher: mass spectrometer, 201510 supply Sciex QTRAP 6500+ Systems for MRM proteomics assays to Stoller Centre	2015-10-28
Univ Manchester–Danaher: mass spectrometer, 201510 supply Sciex TripleTOF 6600 Systems with SWATH Acquisition to Stoller Centre	2015-10-28
Agena Bioscience–Diatech: mass spec-based MDx, 201510– collab developm MassARRAY genomic CDx tests for cancer therapy w Diatech Pharmacogenetics Srl	2015-10-27
Biofrontera–SEVERAL: investment, 201510–201511 capital increase €3.64m net €3.1m with 1.92m new shares at €2/share	2015-10-27
Computomics–High-Tech Gründerfonds: investment, 201510 HTGF invests into Computomics GmbH	2015-10-27
CRISPR Therapeutics–Vertex: investment, 201510 equity investment $30m as part of 4-year research collaboration	2015-10-26
Vertex–CRISPR Therapeutics: CRISPR technology, 201510– collab research $75m upfront + $30m investm + milestones + royalties to treat genetic diseases	2015-10-26
Neuway Pharma–SEVERAL: investment, 201510 financing round Series A Extension €3.15m led by Wellington Partners bringing Series A to €5.85m	2015-10-22
Neuway Pharma–Wellington Partners: investment, 201510 financing round Series A Extension totalling €3.15m incl €2m from Wellington Partners	2015-10-22
Turgut Ilaç–Merck (DE): biosimilar, 201510– supply multi-year of Provantage End-to-End services for developm + production of biologicals	2015-10-22
Admune Therapeutics–Novartis: investment, 201510 acquisition of Admune by Novartis	2015-10-21
Arvinas–SEVERAL: investment, 201510 financing round Series B $41.6m led by RA Capital Management	2015-10-21
Novartis–Palobiofarma: cancer drug, 201510– license developm + commercialisation of adenosine receptor agonist PBF-509	2015-10-21
Novartis–Xoma: antibody cancer drug, 201510– license developm + commercialisation of TGF-beta antibody programs	2015-10-21
Beyond Batten Disease Foundation–Evotec: drug discovery services, 201510–201712 supply service €na assay developm + use for drug discovery	2015-10-20
Noxxon–SEVERAL: investment, 201510– intention to launch IPO of new shares at Euronext Amsterdam + Paris	2015-10-20
Science 37–Novartis: investment, 201510 financing round Series A totalling $6.5m co-led by Lux Capital + dRx Capital	2015-10-20
Science 37–SEVERAL: investment, 201510 financing round Series A $6.5m co-led by Lux Capital + dRx Capital	2015-10-20
Sigma-Aldrich–Honeywell: research chemicals, 201510–201512 acquisition of Sigma-Aldrich research chemicals business by Honewell	2015-10-20
Zellkraftwerk–Helmholtz: investment, 201510 Ascenion acquires equity position under license agreem with MHH for Switch-Antibodies technology	2015-10-20
Zellkraftwerk–MHH: Switch-Antibodies technology, 201510– license ww excl to Zellkraftwerk GmbH from MHH	2015-10-20
Univ Münster–Thermo Fisher: mass spectrometer, 201510 supply Q Exactive GC hybrid quadrupole-Orbitrap GC-MS/MS system to MEET Battery Research Center	2015-10-19
Basilea–SEVERAL: investment, 201510–201512 proposed public offering in the US + listing at Nasdaq Global Market NOT REALISED	2015-10-16
Pronutria–Bertarelli Group: investment, 201510 investment €na by Gurnet Point Capital completing Pronutria’s Series C financing	2015-10-15
Curetis–SEVERAL: investment, 201510–201511 IPO €40m+€4.3m w 4m+431k new shares at €10/share at Euronext Amsterdam + Brussels	2015-10-14
Luxendo–EMBL: investment, 201510 financing round Series A totalling €6m co-led by EMBL Ventures + LSP	2015-10-14
Luxendo–Life Sciences Partners: investment, 201510 financing round Series A totalling €6m co-led by EMBL Ventures + LSP	2015-10-14
Luxendo–SEVERAL: investment, 201510 financing round Series A €6m co-led by EMBL Ventures + LSP	2015-10-14
Minoryx–Chiesi: investment, 201510 financing round Series A totalling €19.4m incl new investor Chiesi Ventures	2015-10-14
Minoryx–HealthEquity (ES): investment, 201510 financing round Series A totalling €19.4m incl existing investor HealthEquity	2015-10-14
Minoryx–Idinvest Partners: investment, 201510 financing round Series A totalling €19.4m incl new investor Idinvest Partners	2015-10-14
Minoryx–Kurma: investment, 201510 financing round Series A totalling €19.4m incl new investor Kurma Partners	2015-10-14
Minoryx–la Caixa: investment, 201510 financing round Series A totalling €19.4m incl existing investor Caixa Capital Risc	2015-10-14
Minoryx–Roche: investment, 201510 financing round Series A totalling €19.4m incl new investor Roche Venture Fund	2015-10-14
Minoryx–SEVERAL: investment, 201510 financing round Series A €19.4m led by Ysios Capital	2015-10-14
Minoryx–Ysios Capital: investment, 201510 financing round Series A totalling €19.4m incl lead investor Ysios Capital	2015-10-14
Zymeworks–Minapharm: GlymaxX technology, 201510– supply service cell line development for bispecific antibody production applying GlymaxX by ProBioGen	2015-10-14

 1 2 3 ... 23 24 25 ... 53 54 55  

Advertisement

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.